Wegovy works by mimicking a natural gut hormone called GLP-1 that controls hunger, fullness, and how quickly food leaves your stomach. The drug’s active ingredient, semaglutide, activates the same receptors as this hormone but lasts far longer in the body, with a half-life of about seven days compared to a few minutes for the natural version. That sustained activity produces several overlapping effects that, together, lead to significant weight loss.
How It Changes Hunger in the Brain
The most powerful thing Wegovy does happens in your brain, not your gut. Semaglutide activates GLP-1 receptors in two key areas. The first is the hypothalamus, which regulates hunger and thirst. NIH researchers mapped a specific neural circuit in the hypothalamus that leads to appetite suppression and weight loss when GLP-1 receptors are activated. The drug essentially tells this circuit that you’ve had enough food, even when you’ve eaten less than usual.
The second brain region involved is the nucleus tractus solitarii, located in the brainstem. When semaglutide activates GLP-1 receptors there, it boosts the activity of serotonin-producing neurons that promote a sense of fullness and reduce the urge to eat. This is why many people on Wegovy describe the experience not as willpower or restriction, but as simply not thinking about food the way they used to. The mental “noise” around eating, the cravings, the constant pull toward snacking, quiets down.
Slower Digestion, Longer Fullness
Wegovy also slows gastric emptying, meaning food stays in your stomach longer after a meal. This sends prolonged fullness signals to your brain and makes smaller portions feel more satisfying. It’s one of the reasons people on the drug often say they can eat half a meal and feel done, when previously they would have finished the whole plate and still wanted more.
This delayed emptying is also behind some of the drug’s most common side effects: nausea, vomiting, and diarrhea, particularly in the early weeks. These tend to improve as the body adjusts, which is why Wegovy uses a gradual dose increase rather than starting at full strength.
The Gradual Ramp-Up
Wegovy starts at 0.25 mg per week and increases every four weeks through four escalation steps: 0.5 mg, then 1 mg, then 1.7 mg, before reaching the 2.4 mg maintenance dose around week 17. This slow titration gives your digestive system time to adapt to the drug’s effects, reducing the intensity of gastrointestinal side effects. Most people tolerate it well by the time they reach the full dose.
Effects Beyond Appetite
Semaglutide doesn’t just reduce hunger. It also improves how your body handles blood sugar by boosting insulin release in response to meals and suppressing glucagon, a hormone that raises blood sugar. These metabolic effects matter even for people without diabetes, because better blood sugar control reduces the insulin spikes that can drive fat storage and energy crashes.
There are cardiovascular benefits too. The SELECT trial, a large study of people with obesity and existing heart disease, found that semaglutide 2.4 mg reduced major cardiovascular events (heart attacks, strokes, and cardiovascular death) by 20% compared to placebo. This result was significant enough that Wegovy became the first weight loss medication also approved to reduce cardiovascular risk.
Why It Works Differently Than Older Weight Loss Drugs
Previous generations of weight loss medications typically targeted a single pathway, often stimulating the central nervous system to suppress appetite, which came with risks like elevated heart rate and dependency. Wegovy works through multiple mechanisms simultaneously: brain-level appetite suppression, slower digestion, improved metabolic signaling, and cardiovascular protection. Because it mimics a hormone your body already produces, the effects feel less like a forced override and more like a recalibration of your natural hunger signals.
It’s also worth noting the difference between Wegovy and Ozempic, since both contain semaglutide. The distinction is dosage and approved use. Wegovy’s maximum maintenance dose is 2.4 mg per week, compared to 2 mg for Ozempic. Wegovy is FDA-approved specifically for chronic weight management, while Ozempic is approved for type 2 diabetes. The higher dose in Wegovy reflects the amount needed to produce meaningful weight loss in people who may not have diabetes.
Why the Effects Reverse When You Stop
One of the most important things to understand about Wegovy is that it treats obesity as a chronic condition, not a temporary one. The drug doesn’t permanently reset your appetite or metabolism. It holds those systems in a different state for as long as you take it. When people stop, their hunger signals and food reward pathways typically return to their pre-treatment baseline, which is why weight regain after discontinuation is common. This isn’t a failure of the drug or the person. It reflects the fact that obesity involves persistent biological drivers, particularly in the brain’s hunger circuitry, that resume once the medication is removed.